EFM
PVLA

E Fund Management’s Palvella Therapeutics PVLA Stock Holding History

E Fund Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$229K Buy
+1,835
New +$191K 0.01% 434

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

E Fund Management's PVLA Position: Q1 2026 in Review

E Fund Management opened a new position in Palvella Therapeutics (PVLA) in Q1 2026: 1,835 shares worth $229K. The stake represents 0.01% of the portfolio and ranks #434 among its holdings.

180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • E Fund Management held 1,835 shares of Palvella Therapeutics worth $229K as of Q1 2026.
  • Palvella Therapeutics was a new E Fund Management position in Q1 2026.
  • Palvella Therapeutics made up 0.01% of E Fund Management's portfolio in Q1 2026, its #434 holding.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on E Fund Management's 13F filing for Q1 2026, filed 13 Apr 2026.